By PPN News Staff
The FDA approved a supplemental Biologics License Application for once-monthly dosing of alirocumab (Praluent, Regeneron/Sanofi) injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic